Immunoglobulin News and Research

RSS

Hepatitis A scare at Long Island church

Health officials have warned that parishioners who received Holy Communion during Christmas Mass at a church on Long Island may have been exposed to hepatitis A and may need vaccinated as soon as possible. Particularly those who received Communion at the 10.30am and 12pm (local time) masses on December 25, 2010, at Our Lady of Lourdes Church in Massapequa Park should get the shots.

4 Jan 2011

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Open Monoclonal Technology, Inc. (OMT) today announced its new human antibody platform using the first genetically engineered rats expressing a human antibody repertoire. The company, which also created the first targeted knockout rats in 2009, is now cross-breeding the knockout animals with the rats expressing human antibodies to finalize its platform.

9 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Radical change to Alzheimer’s management

The first disease-modifying drugs are expected to launch from 2013, radically changing the way Alzheimer’s disease is treated. With the potential to successfully slow or halt the progression of Alzheimer’s, blockbuster revenues are beckoning for such pipeline drugs, claims independent market analyst, Datamonitor.

23 Nov 2010

Grifols launches Flebogamma 10% DIF intravenous immune globulin in the U.S.

Grifols today announced availability of its recently approved Flebogamma® 10% DIF intravenous immune globulin. Grifols is a global healthcare company specializing in bioscience medicines derived from human plasma. Approval from the US Food and Drug Administration (FDA) for Flebogamma® 10% DIF was obtained in July 2010 and final approval in Europe is expected before the end of the year. Today's announcement signals widespread product availability to the US market.

22 Nov 2010

Crescent Healthcare to open infusion pharmacy in New Jersey

Crescent Healthcare today announced a planned expansion of their east coast operations in 2011. They signed a lease to open an infusion pharmacy in Totowa, New Jersey, central to providing immune globulin therapies and services to current patients in Massachusetts, Maryland, New York, New Jersey, Pennsylvania, Connecticut, Delaware, District of Columbia, and Rhode Island.

19 Nov 2010

Science and precedent do not support biosimilar approach for plasma protein therapies

The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.

15 Nov 2010

IBEC researchers discover new group of interacting partners for myelin-associated receptors

It's known that the development of neuronal diseases such as multiple sclerosis and Alzheimer's disease is connected with the levels of myelin - an insulating substance around nerve fibres - in the body, although the actual causes of these conditions remain unknown. Now researchers at IBEC have discovered a new group of interacting partners for myelin-associated receptors, which could shed light on the significance of imbalanced production or modifications of the substance.

12 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

Women with anti-SSA/Ro antibodies and a previous child who has heart block a condition where the electrical signal that makes the heart beat is damaged may potentially decrease their risk of delivering another child with life threatening heart disease by taking hydroxychloroquine (Plaquenil), according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it has created the Interlaken Leadership Awards. This global awards program will provide monetary grants to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders.

29 Oct 2010

Talecris third quarter net revenue increases 2.8% to $407.0 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and nine months ended September 30, 2010 and filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

Pericytes regulate blood-brain barrier

While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.

15 Oct 2010

FDA approves Gamunex-C for primary immunodeficiency treatment

Talecris Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).

15 Oct 2010

Scientists find pericytes regulate blood-brain barrier

14 Oct 2010

Vivaglobin therapy effective for patients with primary immunodeficiency

Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.

7 Oct 2010

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Privigen, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and secondary immunodeficiencies, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. Results also demonstrate that Privigen offers significant protection against infection.

7 Oct 2010

Hizentra therapy effective for primary immunodeficiency patients

Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).

7 Oct 2010

Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID

Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.

From Baxter International Inc. 6 Oct 2010

Immunoglobulin News and Research

Hepatitis A scare at Long Island church

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Radical change to Alzheimer’s management

Grifols launches Flebogamma 10% DIF intravenous immune globulin in the U.S.

Crescent Healthcare to open infusion pharmacy in New Jersey

Science and precedent do not support biosimilar approach for plasma protein therapies

IBEC researchers discover new group of interacting partners for myelin-associated receptors

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

Talecris third quarter net revenue increases 2.8% to $407.0 million

Baxter third quarter net income increases 12% to $595 million

Pericytes regulate blood-brain barrier

FDA approves Gamunex-C for primary immunodeficiency treatment

Scientists find pericytes regulate blood-brain barrier

Vivaglobin therapy effective for patients with primary immunodeficiency

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Hizentra therapy effective for primary immunodeficiency patients

Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News